Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts.

Cheal SM, Ruan S, Veach DR, Longo VA, Punzalan BJ, Wu J, Fung EK, Kelly MP, Kirshner JR, Giurleo JT, Ehrlich G, Han AQ, Thurston G, Olson WC, Zanzonico PB, Larson SM, Carrasquillo JA.

Mol Pharm. 2018 Apr 30. doi: 10.1021/acs.molpharmaceut.7b01133. [Epub ahead of print]

PMID:
29684277
2.

Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids.

Nittoli T, Kelly MP, Delfino F, Rudge J, Kunz A, Markotan T, Spink J, Chen Z, Shan J, Navarro E, Tait M, Provoncha K, Giurleo J, Zhao F, Jiang X, Hylton D, Makonnen S, Hickey C, Kirshner JR, Thurston G, Papadopoulos N.

Bioorg Med Chem. 2018 May 15;26(9):2271-2279. doi: 10.1016/j.bmc.2018.02.025. Epub 2018 Feb 21.

PMID:
29605304
3.

NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim.

Kirshner JJ, McDonald MC 3rd, Kruter F, Guinigundo AS, Vanni L, Maxwell CL, Reiner M, Upchurch TE, Garcia J, Morrow PK.

Support Care Cancer. 2018 Apr;26(4):1323-1334. doi: 10.1007/s00520-017-3959-2. Epub 2017 Nov 16.

4.

The Oncology Care Model: Perspectives From the Centers for Medicare & Medicaid Services and Participating Oncology Practices in Academia and the Community.

Kline R, Adelson K, Kirshner JJ, Strawbridge LM, Devita M, Sinanis N, Conway PH, Basch E.

Am Soc Clin Oncol Educ Book. 2017;37:460-466. doi: 10.14694/EDBK_174909.

5.

Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody-Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers.

Kelly MP, Hickey C, Makonnen S, Coetzee S, Jalal S, Wang Y, Delfino F, Shan J, Potocky TB, Chatterjee I, Andreev J, Kunz A, D'Souza C, Giurleo JT, Nittoli T, Trail PA, Thurston G, Kirshner JR.

Mol Cancer Ther. 2017 Jul;16(7):1299-1311. doi: 10.1158/1535-7163.MCT-16-0839. Epub 2017 Apr 4.

PMID:
28377489
6.

Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.

Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O'Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett E, Carey L, Dickler M, Heist RS, Himelstein A, Rugo HS, Sikov WM, Socinski MA, Venook AP, Weckstein DJ, Lake DE, Biggs DD, Freedman RA, Kuzma C, Kirshner JJ, Schrag D.

JAMA Oncol. 2017 Aug 1;3(8):1043-1050. doi: 10.1001/jamaoncol.2016.6749.

PMID:
28208174
7.

Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs.

Andreev J, Thambi N, Perez Bay AE, Delfino F, Martin J, Kelly MP, Kirshner JR, Rafique A, Kunz A, Nittoli T, MacDonald D, Daly C, Olson W, Thurston G.

Mol Cancer Ther. 2017 Apr;16(4):681-693. doi: 10.1158/1535-7163.MCT-16-0658. Epub 2017 Jan 20.

8.

Reply to L.B. Marks et al.

Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, Hudis CA, Hwang ES, Kirshner JJ, Morrow M, Salerno KE, Sledge GW Jr, Solin LJ, Spears PA, Whelan TJ, Somerfield MR, Edge SB.

J Clin Oncol. 2017 Apr 10;35(11):1258-1259. doi: 10.1200/JCO.2016.71.3966. Epub 2017 Jan 9. No abstract available.

PMID:
28068171
9.

Screening for depression in cancer patients receiving radiotherapy: Feasibility and identification of effective tools in the NRG Oncology RTOG 0841 trial.

Wagner LI, Pugh SL, Small W Jr, Kirshner J, Sidhu K, Bury MJ, DeNittis AS, Alpert TE, Tran B, Bloom BF, Mai J, Yeh A, Sarma K, Becker M, James J, Bruner DW.

Cancer. 2017 Feb 1;123(3):485-493. doi: 10.1002/cncr.29969. Epub 2016 Nov 10.

10.

15-Methylene-Eburnamonine Kills Leukemic Stem Cells and Reduces Engraftment in a Humanized Bone Marrow Xenograft Mouse Model of Leukemia.

Gunasekara DC, Zheng MM, Mojtahed T, Woods JR, Fandy TE, Riofski MV, Glackin CA, Hassan HE, Kirshner J, Colby DA.

ChemMedChem. 2016 Sep 28. doi: 10.1002/cmdc.201600334. [Epub ahead of print]

11.

Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.

Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, Hudis CA, Hwang ES, Kirshner JJ, Morrow M, Salerno KE, Sledge GW Jr, Solin LJ, Spears PA, Whelan TJ, Somerfield MR, Edge SB.

Pract Radiat Oncol. 2016 Nov - Dec;6(6):e219-e234. doi: 10.1016/j.prro.2016.08.009. Epub 2016 Sep 19. Review.

PMID:
27659727
12.

Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.

Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, Hudis CA, Hwang ES, Kirshner JJ, Morrow M, Salerno KE, Sledge GW Jr, Solin LJ, Spears PA, Whelan TJ, Somerfield MR, Edge SB.

J Clin Oncol. 2016 Dec 20;34(36):4431-4442. doi: 10.1200/JCO.2016.69.1188. Epub 2016 Sep 30. Review.

PMID:
27646947
13.

Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.

Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, Hudis CA, Hwang ES, Kirshner JJ, Morrow M, Salerno KE, Sledge GW Jr, Solin LJ, Spears PA, Whelan TJ, Somerfield MR, Edge SB.

Ann Surg Oncol. 2017 Jan;24(1):38-51. doi: 10.1245/s10434-016-5558-8. Epub 2016 Sep 19.

14.

1α,25-Dihydroxyvitamin D Inhibits the Metastatic Capability of MCF10CA1a and MDA-MB-231 Cells in an In Vitro Model of Breast to Bone Metastasis.

Wilmanski T, Barnard A, Parikh MR, Kirshner J, Buhman K, Burgess J, Teegarden D.

Nutr Cancer. 2016 Oct;68(7):1202-9. doi: 10.1080/01635581.2016.1213868. Epub 2016 Aug 23.

15.

In-silico discovery of cancer-specific peptide-HLA complexes for targeted therapy.

Dhanik A, Kirshner JR, MacDonald D, Thurston G, Lin HC, Murphy AJ, Zhang W.

BMC Bioinformatics. 2016 Jul 20;17:286. doi: 10.1186/s12859-016-1150-2.

16.

Maytansinoid immunoconjugate IMGN901 is cytotoxic in a three-dimensional culture model of multiple myeloma.

Nierste BA, Gunn EJ, Whiteman KR, Lutz RJ, Kirshner J.

Am J Blood Res. 2016 May 18;6(1):6-18. eCollection 2016.

17.

A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.

Smith EJ, Olson K, Haber LJ, Varghese B, Duramad P, Tustian AD, Oyejide A, Kirshner JR, Canova L, Menon J, Principio J, MacDonald D, Kantrowitz J, Papadopoulos N, Stahl N, Yancopoulos GD, Thurston G, Davis S.

Sci Rep. 2015 Dec 11;5:17943. doi: 10.1038/srep17943.

18.

Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.

Kuhnert F, Chen G, Coetzee S, Thambi N, Hickey C, Shan J, Kovalenko P, Noguera-Troise I, Smith E, Fairhurst J, Andreev J, Kirshner JR, Papadopoulos N, Thurston G.

Cancer Res. 2015 Oct 1;75(19):4086-96. doi: 10.1158/0008-5472.CAN-14-3773. Epub 2015 Sep 16.

19.

Buspirone for management of dyspnea in cancer patients receiving chemotherapy: a randomized placebo-controlled URCC CCOP study.

Peoples AR, Bushunow PW, Garland SN, Heckler CE, Roscoe JA, Peppone LL, Dudgeon DJ, Kirshner JJ, Banerjee TK, Hopkins JO, Dakhil SR, Flannery MA, Morrow GR.

Support Care Cancer. 2016 Mar;24(3):1339-47. doi: 10.1007/s00520-015-2903-6. Epub 2015 Sep 2.

20.

The effect of YOCAS©® yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy.

Peppone LJ, Janelsins MC, Kamen C, Mohile SG, Sprod LK, Gewandter JS, Kirshner JJ, Gaur R, Ruzich J, Esparaz BT, Mustian KM.

Breast Cancer Res Treat. 2015 Apr;150(3):597-604. doi: 10.1007/s10549-015-3351-1. Epub 2015 Mar 27.

21.

A reconstructed metastasis model to recapitulate the metastatic spread in vitro.

Parikh MR, Minser KE, Rank LM, Glackin CA, Kirshner J.

Biotechnol J. 2014 Sep;9(9):1129-39. doi: 10.1002/biot.201400121. Epub 2014 Jul 7.

22.

Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.

Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Gonzalez-Angulo AM, Kirshner JJ, Krop I, Levinson J, Modi S, Patt DA, Perez EA, Perlmutter J, Winer EP, Lin NU.

J Clin Oncol. 2014 Jul 1;32(19):2100-8. doi: 10.1200/JCO.2013.54.0955. Epub 2014 May 5. Review.

PMID:
24799487
23.

Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.

Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J, Lin NU, Modi S, Patt DA, Perez EA, Perlmutter J, Ramakrishna N, Winer EP; American Society of Clinical Oncology.

J Clin Oncol. 2014 Jul 1;32(19):2078-99. doi: 10.1200/JCO.2013.54.0948. Epub 2014 May 5. Review.

PMID:
24799465
24.

A three-dimensional tissue culture model to study primary human bone marrow and its malignancies.

Parikh MR, Belch AR, Pilarski LM, Kirshner J.

J Vis Exp. 2014 Mar 8;(85). doi: 10.3791/50947.

25.

A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors.

Gewandter JS, Mohile SG, Heckler CE, Ryan JL, Kirshner JJ, Flynn PJ, Hopkins JO, Morrow GR.

Support Care Cancer. 2014 Jul;22(7):1807-14. doi: 10.1007/s00520-014-2158-7. Epub 2014 Feb 16.

26.

N-cadherin impedes proliferation of the multiple myeloma cancer stem cells.

Sadler NM, Harris BR, Metzger BA, Kirshner J.

Am J Blood Res. 2013 Dec 18;3(4):271-85. eCollection 2013.

27.

Dkk-1 and IL-7 in plasma of patients with multiple myeloma prevent differentiation of mesenchymal stem cells into osteoblasts.

Nierste BA, Glackin CA, Kirshner J.

Am J Blood Res. 2014 Dec 15;4(2):73-85. eCollection 2014.

28.

Differentiation of cancer cells in two-dimensional and three-dimensional breast cancer models by Raman spectroscopy.

Damayanti NP, Fang Y, Parikh MR, Craig AP, Kirshner J, Irudayaraj J.

J Biomed Opt. 2013 Nov;18(11):117008. doi: 10.1117/1.JBO.18.11.117008.

29.

Synthesis of 15-methylene-eburnamonine from (+)-vincamine, evaluation of anticancer activity, and investigation of mechanism of action by quantitative NMR.

Woods JR, Riofski MV, Zheng MM, O'Banion MA, Mo H, Kirshner J, Colby DA.

Bioorg Med Chem Lett. 2013 Nov 1;23(21):5865-9. doi: 10.1016/j.bmcl.2013.08.095. Epub 2013 Sep 6.

30.

The systemic cytokine environment is permanently altered in multiple myeloma.

Zheng MM, Zhang Z, Bemis K, Belch AR, Pilarski LM, Shively JE, Kirshner J.

PLoS One. 2013;8(3):e58504. doi: 10.1371/journal.pone.0058504. Epub 2013 Mar 27.

31.

Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.

Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani V, Stepanski EJ, Rugo HS, Wang W, Bell-McGuinn K, Kirshner JJ, Eisenberg P, Emanuelson R, Keaton M, Levine E, Medgyesy DC, Qamar R, Starr A, Ro SK, Lokker NA, Hudis CA.

Clin Cancer Res. 2013 May 15;19(10):2745-54. doi: 10.1158/1078-0432.CCR-12-3177. Epub 2013 Feb 26.

32.

A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors.

Lavigne JE, Heckler C, Mathews JL, Palesh O, Kirshner JJ, Lord R, Jacobs A, Amos E, Morrow GR, Mustian K.

Breast Cancer Res Treat. 2012 Nov;136(2):479-86. doi: 10.1007/s10549-012-2251-x. Epub 2012 Oct 2.

33.

Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base.

Kirshner JJ, Heckler CE, Janelsins MC, Dakhil SR, Hopkins JO, Coles C, Morrow GR.

J Clin Oncol. 2012 Jun 1;30(16):1974-9. doi: 10.1200/JCO.2011.37.8364. Epub 2012 Apr 16.

34.

Dll4-Notch signaling as a therapeutic target in tumor angiogenesis.

Kuhnert F, Kirshner JR, Thurston G.

Vasc Cell. 2011 Sep 18;3(1):20. doi: 10.1186/2045-824X-3-20.

35.

Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients.

Ryan JL, Heckler CE, Roscoe JA, Dakhil SR, Kirshner J, Flynn PJ, Hickok JT, Morrow GR.

Support Care Cancer. 2012 Jul;20(7):1479-89. doi: 10.1007/s00520-011-1236-3. Epub 2011 Aug 5.

36.

Ongoing Dll4-Notch signaling is required for T-cell homeostasis in the adult thymus.

Billiard F, Kirshner JR, Tait M, Danave A, Taheri S, Zhang W, Waite JC, Olson K, Chen G, Coetzee S, Hylton D, Murphy AJ, Yancopoulos GD, Thurston G, Skokos D.

Eur J Immunol. 2011 Aug;41(8):2207-16. doi: 10.1002/eji.201041343. Epub 2011 Jul 4.

37.

Exploiting the facile release of trifluoroacetate for the α-methylenation of the sterically hindered carbonyl groups on (+)-sclareolide and (-)-eburnamonine.

Riofski MV, John JP, Zheng MM, Kirshner J, Colby DA.

J Org Chem. 2011 May 20;76(10):3676-83. doi: 10.1021/jo102114f. Epub 2011 Apr 14.

PMID:
21491928
38.

The natural products parthenolide and andrographolide exhibit anti-cancer stem cell activity in multiple myeloma.

Gunn EJ, Williams JT, Huynh DT, Iannotti MJ, Han C, Barrios FJ, Kendall S, Glackin CA, Colby DA, Kirshner J.

Leuk Lymphoma. 2011 Jun;52(6):1085-97. doi: 10.3109/10428194.2011.555891. Epub 2011 Mar 21.

PMID:
21417826
39.

Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401.

Hurria A, Cirrincione CT, Muss HB, Kornblith AB, Barry W, Artz AS, Schmieder L, Ansari R, Tew WP, Weckstein D, Kirshner J, Togawa K, Hansen K, Katheria V, Stone R, Galinsky I, Postiglione J, Cohen HJ.

J Clin Oncol. 2011 Apr 1;29(10):1290-6. doi: 10.1200/JCO.2010.30.6985. Epub 2011 Feb 28.

40.

Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.

Shapiro CL, Halabi S, Hars V, Archer L, Weckstein D, Kirshner J, Sikov W, Winer E, Burstein HJ, Hudis C, Isaacs C, Schilsky R, Paskett E.

Eur J Cancer. 2011 Mar;47(5):683-9. doi: 10.1016/j.ejca.2010.11.024. Epub 2011 Feb 14.

41.

In a patient with biclonal Waldenstrom macroglobulinemia only one clone expands in three-dimensional culture and includes putative cancer stem cells.

Kirshner J, Thulien KJ, Kriangkum J, Motz S, Belch AR, Pilarski LM.

Leuk Lymphoma. 2011 Feb;52(2):285-9. doi: 10.3109/10428194.2010.535183. Epub 2010 Dec 6.

PMID:
21133724
42.

Race/ethnicity-based concerns over understanding cancer diagnosis and treatment plan.

Jean-Pierre P, Fiscella K, Griggs J, Joseph JV, Morrow G, Carroll J, Hendren S, Purnell J, Figueroa-Moseley C, Kuebler P, Banerjee TK, Kirshner JJ.

J Natl Med Assoc. 2010 Mar;102(3):184-9.

43.

A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer.

Hortobagyi GN, Heim W, Hutchins L, Rivera E, Mason B, Booser DJ, Kirshner J.

Cancer. 2010 Mar 15;116(6):1440-5. doi: 10.1002/cncr.24900.

44.

Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.

Lilenbaum R, Wang X, Gu L, Kirshner J, Lerro K, Vokes E.

J Clin Oncol. 2009 Sep 20;27(27):4487-91. doi: 10.1200/JCO.2009.22.7066. Epub 2009 Aug 24.

45.

Information-seeking styles among cancer patients before and after treatment by demographics and use of information sources.

Eheman CR, Berkowitz Z, Lee J, Mohile S, Purnell J, Rodriguez EM, Roscoe J, Johnson D, Kirshner J, Morrow G.

J Health Commun. 2009 Jul-Aug;14(5):487-502. doi: 10.1080/10810730903032945.

46.

Sexual Adjustment and Body Image Scale (SABIS): a new measure for breast cancer patients.

Dalton EJ, Rasmussen VN, Classen CC, Grumann M, Palesh OG, Zarcone J, Kraemer HC, Kirshner JJ, Colman LK, Morrow GR, Spiegel D.

Breast J. 2009 May-Jun;15(3):287-90. doi: 10.1111/j.1524-4741.2009.00718.x.

47.

Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance.

Tancred TM, Belch AR, Reiman T, Pilarski LM, Kirshner J.

J Histochem Cytochem. 2009 Mar;57(3):239-47. doi: 10.1369/jhc.2008.952200. Epub 2008 Nov 11.

48.

Elesclomol induces cancer cell apoptosis through oxidative stress.

Kirshner JR, He S, Balasubramanyam V, Kepros J, Yang CY, Zhang M, Du Z, Barsoum J, Bertin J.

Mol Cancer Ther. 2008 Aug;7(8):2319-27. doi: 10.1158/1535-7163.MCT-08-0298.

49.

A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma.

Kirshner J, Thulien KJ, Martin LD, Debes Marun C, Reiman T, Belch AR, Pilarski LM.

Blood. 2008 Oct 1;112(7):2935-45. doi: 10.1182/blood-2008-02-142430. Epub 2008 Jun 5.

50.

Effect of a nausea expectancy manipulation on chemotherapy-induced nausea: a university of Rochester cancer center community clinical oncology program study.

Shelke AR, Roscoe JA, Morrow GR, Colman LK, Banerjee TK, Kirshner JJ.

J Pain Symptom Manage. 2008 Apr;35(4):381-7. doi: 10.1016/j.jpainsymman.2007.05.008. Epub 2008 Feb 4.

Supplemental Content

Loading ...
Support Center